Trial · NCT07905261
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07905261, Phase 1, Phase 2, Not yet recruiting, Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Trials, record NCT07905261. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905261
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- NCT number
- NCT07905261
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 384 participants, estimated
- Lead sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
- Conditions
- Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- SYS6055
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-limiting toxicities (DLTs) | Dose-limiting toxicities (DLTs) will be assessed 28 days after the first dose. | |
| Primary | Occurrence of Adverse Events (AE) | Up to 24 months after administration of 6055 | |
| Primary | Occurrence of Serious Adverse Events (SAE) | Up to 24 months after administration of 6055 | |
| Primary | Recommended Phase 2 Dose (RP2D) of SYS6055 | through study completion, an average of 3 years | |
| Primary | Maximum Tolerated Dose (MTD) of SYS6055 | through study completion, an average of 3 years | |
| Secondary | Objective Response Rate (ORR) | through study completion, an average of 3 years | |
| Secondary | Time to Response（TTR ） | through study completion, an average of 3 years | |
| Secondary | Duration of Response (DoR) | through study completion, an average of 3 years | |
| Secondary | Progression-free survival (PFS) | through study completion, an average of 3 years | |
| Secondary | Overall Survival (OS) | through study completion, an average of 3 years |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905261
GET https://conductscience.org/api/trials/v1/NCT07905261/registered?page=2